Early Inhaled Budesonide for the Prevention of Bronche

New England Journal of Medicine 373, 1497-1506 DOI: 10.1056/nejmoa1501917

Citation Report

#	Article	IF	CITATIONS
1	No End to Uncertainty about Inhaled Glucocorticoids in Preterm Infants. New England Journal of Medicine, 2015, 373, 1566-1567.	27.0	8
2	Biomarkers for Bronchopulmonary Dysplasia in the Preterm Infant. Frontiers in Pediatrics, 2016, 4, 33.	1.9	61
3	Where Are We Now with the Role of Steroids in the Management of Bronchopulmonary Dysplasia in Extremely Premature Babies?. Frontiers in Pediatrics, 2016, 4, 85.	1.9	0
4	Systematic Review of Inhaled Bronchodilator and Corticosteroid Therapies in Infants with Bronchopulmonary Dysplasia: Implications and Future Directions. PLoS ONE, 2016, 11, e0148188.	2.5	39
5	Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. South African Respiratory Journal, 2016, 22, 27.	0.0	0
6	Hydrocortisone use in ventilated extremely preterm infants decreased bronchopulmonary dysplasia with no effects on neurodevelopment after two years. Acta Paediatrica, International Journal of Paediatrics, 2016, 105, 1047-1055.	1.5	5
7	Short- and Long-Term Outcomes for Extremely Preterm Infants. American Journal of Perinatology, 2016, 33, 318-328.	1.4	226
8	Anti-inflammatory Agents for the Prevention of Bronchopulmonary Dysplasia. Respiratory Medicine, 2016, , 325-344.	0.1	1
10	Mechanisms of Lung Injury and Bronchopulmonary Dysplasia. American Journal of Perinatology, 2016, 33, 1076-1078.	1.4	170
11	Maternal Alcohol Use During Pregnancy and Associated Morbidities in Very Low Birth Weight Newborns. American Journal of the Medical Sciences, 2016, 352, 368-375.	1.1	13
12	Lung Diseases: Problems of Steroid Treatment of Fetus and Newborn. , 2016, , 1-7.		0
14	Systemic Corticosteroids for the Prevention of Bronchopulmonary Dysplasia: Picking the Right Drug for the Right Baby. Neonatal Network: NN, 2016, 35, 234-239.	0.3	4
15	Inhaled Corticosteroids for Bronchopulmonary Dysplasia: A Meta-analysis. Pediatrics, 2016, 138, .	2.1	58
16	Bronchopulmonary Dysplasia/Chronic Lung Disease of the Newborn. , 2016, , 1-25.		0
17	Early inhaled steroid use in extremely low birthweight infants: a randomised controlled trial. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2016, 101, F552-F556.	2.8	33
18	CRISPLD2 (LGL1) inhibits proinflammatory mediators in human fetal, adult, and COPD lung fibroblasts and epithelial cells. Physiological Reports, 2016, 4, e12942.	1.7	24
19	Phosphatidylcholine kinetics in neonatal rat lungs and the effects of rhuKGF and betamethasone. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 310, L955-L963.	2.9	8
21	Reply. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 372-373.	3.8	0

#	Article	IF	CITATIONS
22	Antiinflammatory Effects of Budesonide in Human Fetal Lung. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 623-632.	2.9	33
23	Stem cell–based therapies for the newborn lung and brain: Possibilities and challenges. Seminars in Perinatology, 2016, 40, 138-151.	2.5	64
25	Inhaled Corticosteroids for Asthma Therapy in Young Children: Does Aerosol Particle Size Matter?. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 372.	3.8	2
26	The Search for Treatment of Bronchopulmonary Dysplasia. JAMA Pediatrics, 2016, 170, 322.	6.2	9
27	Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates. The Cochrane Library, 2020, 2020, CD001969.	2.8	81
28	Does early treatment with inhaled budesonide prevent death or bronchopulmonary dysplasia in extremely preterm infants?. Acta Paediatrica, International Journal of Paediatrics, 2017, 106, 683-683.	1.5	2
29	The roles of drug therapy given via the endotracheal tube to neonates. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2017, 102, F277-F281.	2.8	1
30	Adjunctive Therapies in Bronchopulmonary Dysplasia. NeoReviews, 2017, 18, e173-e179.	0.8	4
31	Intratracheal Administration of Budesonide‣urfactant in Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants: A Systematic Review and Metaâ€Analysis. Pediatric Pulmonology, 2017, 52, 968-975.	2.0	72
32	Advances in emerging treatment options to prevent bronchopulmonary dysplasia. Expert Opinion on Orphan Drugs, 2017, , 1-11.	0.8	0
33	The evolution of modern respiratory care for preterm infants. Lancet, The, 2017, 389, 1649-1659.	13.7	112
34	Inhaled Glucocorticoids and Pneumonia in Preterm Infants: Post Hoc Results from the NEuroSIS Trial. Neonatology, 2017, 112, 110-113.	2.0	9
35	Update on Postnatal Steroids. Neonatology, 2017, 111, 415-422.	2.0	53
36	Caffeine modulates glucocorticoid-induced expression of CTGF in lung epithelial cells and fibroblasts. Respiratory Research, 2017, 18, 51.	3.6	27
37	Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age. JAMA - Journal of the American Medical Association, 2017, 317, 1329.	7.4	99
38	Inhaled Drugs and Systemic Corticosteroids for Bronchopulmonary Dysplasia. Pediatric Clinics of North America, 2017, 64, 1355-1367.	1.8	11
39	Can We Prevent Bronchopulmonary Dysplasia?. Journal of Pediatrics, 2017, 189, 26-30.	1.8	23
40	Early hydrocortisone improves survival without bronchopulmonary dysplasia in extremely preterm born infants. Acta Paediatrica, International Journal of Paediatrics, 2017, 106, 2067-2067.	1.5	0

#	Article	IF	CITATIONS
41	Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates. The Cochrane Library, 2020, 2020, CD002058.	2.8	29
42	Ventilation in Preterm Infants and Lung Function at 8 Years. New England Journal of Medicine, 2017, 377, 1599-1602.	27.0	12
43	Instantaneous Wave-free Ratio versus Fractional Flow Reserve. New England Journal of Medicine, 2017, 377, 1595-1599.	27.0	17
44	Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia – Who might benefit?. Seminars in Fetal and Neonatal Medicine, 2017, 22, 290-295.	2.3	22
45	Efficient Interfacially Driven Vehiculization of Corticosteroids by Pulmonary Surfactant. Langmuir, 2017, 33, 7929-7939.	3.5	35
46	In vitro and in vivo characterization of poractant alfa supplemented with budesonide for safe and effective intratracheal administration. Pediatric Research, 2017, 82, 1056-1063.	2.3	27
47	Sharing Progress in Neonatal (SPIN) Brain, Gut, Heart, and Lung. Neonatology, 2017, 111, 384-387.	2.0	4
48	The use of inhaled corticosteroids in chronically ventilated preterm infants. Seminars in Fetal and Neonatal Medicine, 2017, 22, 296-301.	2.3	13
49	II. Topic Sessions. Pediatric Pulmonology, 2017, 52, S32-S93.	2.0	4
50	Inhaled hydrofluoalkane-beclomethasone dipropionate in bronchopulmonary dysplasia. A double-blind, randomized, controlled pilot study. Journal of Perinatology, 2017, 37, 197-202.	2.0	14
51	Inhaled budesonide for the prevention of bronchopulmonary dysplasia. Journal of Maternal-Fetal and Neonatal Medicine, 2017, 30, 2372-2374.	1.5	12
52	European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2016 Update. Neonatology, 2017, 111, 107-125.	2.0	399
53	Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants. The Cochrane Library, 2020, 2020, CD002057.	2.8	23
54	Efficacy of glucocorticoids, vitamin A and caffeine therapies for neonatal mortality in preterm infants: a network meta-analysis. Oncotarget, 2017, 8, 81167-81175.	1.8	1
55	Respiratory Distress Syndrome: Predisposing Factors, Pathophysiology, and Diagnosis. , 2017, , 1-20.		0
56	Pharmacologic Therapies IV. , 2017, , 366-379.e5.		7
57	La dysplasie bronchopulmonaire. , 2017, , 283-299.		0
58	The Future of Bronchopulmonary Dysplasia: Emerging Pathophysiological Concepts and Potential New Avenues of Treatment. Frontiers in Medicine, 2017, 4, 61.	2.6	79

#	Article	IF	CITATIONS
59	Airway administration of corticosteroids for prevention of bronchopulmonary dysplasia in premature infants: a meta-analysis with trial sequential analysis. BMC Pulmonary Medicine, 2017, 17, 207.	2.0	18
60	Evidence-Based Respiratory Care. , 2017, , 41-48.e1.		0
61	Existe-t-il (encore) une place pourÂla corticothérapie postnatale chez le nouveau-né prématuréÂ?. , 201 157-163.	7,,	0
62	Persistent and progressive long-term lung disease in survivors of preterm birth. Paediatric Respiratory Reviews, 2018, 28, 87-94.	1.8	37
63	Safety and Efficacy of Inhaled Steroids in Premature Infants. AAP Grand Rounds, 2018, 39, 46-46.	0.0	0
64	Prevention of bronchopulmonary dysplasia in extremely low gestational age neonates: current evidence. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2018, 103, F285-F291.	2.8	81
65	Use of Glucocorticoids for the Fetus and Preterm Infant. Clinics in Perinatology, 2018, 45, 93-102.	2.1	13
66	Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia. New England Journal of Medicine, 2018, 378, 148-157.	27.0	107
67	Bronchopulmonary dysplasia: clinical aspects and preventive and therapeutic strategies. Journal of Translational Medicine, 2018, 16, 36.	4.4	156
68	Bronchopulmonary Dysplasia: The Ongoing Search for One Definition to Rule Them All. Journal of Pediatrics, 2018, 197, 8-10.	1.8	29
69	Bronchopulmonary Dysplasia: Executive Summary of a Workshop. Journal of Pediatrics, 2018, 197, 300-308.	1.8	516
70	Postnatal steroids in extreme preterm infants: Intra-tracheal instillation using surfactant as a vehicle. Paediatric Respiratory Reviews, 2018, 25, 78-84.	1.8	6
71	Growth and morbidity of extremely preterm infants after early full enteral nutrition. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2018, 103, F79-F81.	2.8	35
72	Inhaled and systemic steroid exposure and neurodevelopmental outcome of preterm neonates. Journal of Maternal-Fetal and Neonatal Medicine, 2018, 31, 2665-2672.	1.5	13
73	A Time-Based Analysis of Inflammation in Infants at Risk of Bronchopulmonary Dysplasia. Journal of Pediatrics, 2018, 192, 60-65.e1.	1.8	50
74	Are inhaled steroids safe and effective for prevention or treatment of bronchopulmonary dysplasia?. Acta Paediatrica, International Journal of Paediatrics, 2018, 107, 554-556.	1.5	8
75	Developmental Pharmacokinetics in Neonates: Maturational Changes and Beyond. Current Pharmaceutical Design, 2018, 23, 5769-5778.	1.9	29
76	Bronchopulmonary Dysplasia: An Update of Current Pharmacologic Therapies and New Approaches. Clinical Medicine Insights Pediatrics, 2018, 12, 117955651881732.	1.4	55

#	Article	IF	CITATIONS
77	Does inhaled budesonide for bronchopulmonary dysplasia affect the neurodevelopmental outcomes?. Journal of Perinatology, 2018, 38, 1607-1609.	2.0	2
78	Surfactant, steroids and non-invasive ventilation in the prevention of BPD. Seminars in Perinatology, 2018, 42, 444-452.	2.5	39
79	An update on the post-NICU discharge management of bronchopulmonary dysplasia. Seminars in Perinatology, 2018, 42, 471-477.	2.5	20
80	Recomendaciones del VIII Consenso ClÃnico de SIBEN para la Displasia Broncopulmonar. NeoReviews, 2018, 19, e712-e734.	0.8	5
81	Respiratory Distress Syndrome: Predisposing Factors, Pathophysiology, and Diagnosis. , 2018, , 823-842.		1
82	Investigation and management of the long-term ventilated premature infant. Early Human Development, 2018, 126, 10-17.	1.8	10
83	Postnatal steroids: still a dilemma for neonatologists and parents?. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2018, 103, F500-F502.	2.8	4
84	Effects of budesonide and surfactant in preterm fetal sheep. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L193-L201.	2.9	30
85	Neonatal Sepsis of Early Onset, and Hospital-Acquired and Community-Acquired Late Onset: A Prospective Population-Based Cohort Study. Journal of Pediatrics, 2018, 201, 106-114.e4.	1.8	150
86	Bronchopulmonary dysplasia: what's new on the horizon?. The Lancet Child and Adolescent Health, 2018, 2, 549-551.	5.6	10
87	Inhaled corticosteroids in ventilated preterm neonates: a non-randomized dose-ranging study. BMC Pediatrics, 2018, 18, 153.	1.7	7
88	Bronchopulmonary Dysplasia. , 2018, , 678-694.e6.		2
89	Bronchopulmonary Dysplasia. , 2018, , 56-57.		0
90	Bronchopulmonary Dysplasia. , 2019, , 367-381.e5.		1
91	Longâ€ŧerm effects of the intratracheal administration of corticosteroids for the prevention of bronchopulmonary dysplasia: A metaâ€analysis. Pediatric Pulmonology, 2019, 54, 1722-1734.	2.0	6
92	Meteredâ€dose inhaler therapy with spacers: Are newborns capable of using this system correctly?. Pediatric Pulmonology, 2019, 54, 1417-1421.	2.0	6
93	Update on Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia. American Journal of Perinatology, 2019, 36, S58-S62.	1.4	25
94	Bronchopulmonary dysplasia as a trial endpoint: time for re-evaluation?. The Lancet Child and Adolescent Health, 2019, 3, 842-844.	5.6	6

#	Article	IF	CITATIONS
95	Antenatal and postnatal corticosteroids: Knowledge gaps and research priorities. Seminars in Fetal and Neonatal Medicine, 2019, 24, 213-215.	2.3	0
96	Alternatives to systemic postnatal corticosteroids: Inhaled, nebulized and intratracheal. Seminars in Fetal and Neonatal Medicine, 2019, 24, 207-212.	2.3	7
97	European Consensus Guidelines on the Management of Respiratory Distress Syndrome – 2019 Update. Neonatology, 2019, 115, 432-450.	2.0	780
98	Prevention of Bronchopulmonary Dysplasia: A Summary of Evidence-Based Strategies. NeoReviews, 2019, 20, e189-e201.	0.8	21
99	Inhaled surfactant plus budesonide reduces early preterm lung injury, but is there an effect beyond the lung?. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L886-L887.	2.9	0
100	Long-term effects of postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia: Balancing the risks and benefits. Seminars in Fetal and Neonatal Medicine, 2019, 24, 197-201.	2.3	15
101	Drugs for the Prevention and Treatment of Bronchopulmonary Dysplasia. Clinics in Perinatology, 2019, 46, 291-310.	2.1	39
102	Respiratory syncytial virus prophylaxis for children with chronic lung disease: have we got the criteria right?. Expert Review of Anti-Infective Therapy, 2019, 17, 211-222.	4.4	5
103	Local pulmonary drug delivery in the preterm rabbit: feasibility and efficacy of daily intratracheal injections. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L589-L597.	2.9	17
104	A systematic review identifying common data items in neonatal trials and assessing their completeness in routinely recorded United Kingdom national neonatal data. Trials, 2019, 20, 731.	1.6	4
105	Bronchopulmonary dysplasia. Nature Reviews Disease Primers, 2019, 5, 78.	30.5	541
106	Inhibition of chlorine-induced airway fibrosis by budesonide. Toxicology and Applied Pharmacology, 2019, 363, 11-21.	2.8	11
107	Prenatal and Postnatal Steroids and Pulmonary Outcomes. , 2019, , 335-346.		1
108	Efficacy and safety of pulmonary application of corticosteroids in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2019, 104, F137-F144.	2.8	21
109	The impact of inhaled bronchodilators on bronchopulmonary dysplasia: a nonrandomized comparison from the NEuroSIS trial. Journal of Maternal-Fetal and Neonatal Medicine, 2020, 33, 4030-4032.	1.5	5
110	Surfactant and budesonide for respiratory distress syndrome: an observational study. Pediatric Research, 2020, 87, 940-945.	2.3	33
111	L'administration postnatale de corticostéroÃ⁻des pour prévenir ou traiter la dysplasie bronchopulmonaire chez les nouveau-nés prématurés. Paediatrics and Child Health, 2020, 25, 327-331.	0.6	0
112	Tackling bronchopulmonary dysplasia to improve preterm health: a call for family-centered care at World Prematurity Day 2020. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L867-L870.	2.9	9

#	Article	IF	CITATIONS
113	Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia in preterm infants. Paediatrics and Child Health, 2020, 25, 322-326.	0.6	30
114	Effects of Liberal vs Restrictive Transfusion Thresholds on Survival and Neurocognitive Outcomes in Extremely Low-Birth-Weight Infants. JAMA - Journal of the American Medical Association, 2020, 324, 560.	7.4	134
115	Decreased neutrophil levels in bronchopulmonary dysplasia infants. Pediatrics and Neonatology, 2020, 61, 637-644.	0.9	5
116	Phenotypes of Bronchopulmonary Dysplasia. International Journal of Molecular Sciences, 2020, 21, 6112.	4.1	36
117	History of caffeine use in neonatal medicine and the role of the CAP trial. Seminars in Fetal and Neonatal Medicine, 2020, 25, 101159.	2.3	1
118	Treatment and respiratory support modes for neonates with respiratory distress syndrome. Expert Opinion on Orphan Drugs, 2020, 8, 145-156.	0.8	0
119	Present and Future of Bronchopulmonary Dysplasia. Journal of Clinical Medicine, 2020, 9, 1539.	2.4	75
120	Role of Nutrition in Prevention of Neonatal Spontaneous Intestinal Perforation and Its Complications: A Systematic Review. Nutrients, 2020, 12, 1347.	4.1	9
121	Early inhaled budesonide in extremely preterm infants decreases longâ€ŧerm respiratory morbidity. Pediatric Pulmonology, 2020, 55, 1124-1130.	2.0	8
122	Systemic and topical glucocorticoids to prevent BPD. , 2020, , 3-19.		0
123	Dose-escalation trial of budesonide in surfactant for prevention of bronchopulmonary dysplasia in extremely low gestational age high-risk newborns (SASSIE). Pediatric Research, 2020, 88, 629-636.	2.3	21
124	Dose of budesonide with surfactant affects lung and systemic inflammation after normal and injurious ventilation in preterm lambs. Pediatric Research, 2020, 88, 726-732.	2.3	12
125	Pharmacological Therapies for the Prevention of Bronchopulmonary Dysplasia. , 2020, , 245-256.		0
126	Extended Pharmacopeial Characterization of Surfactant Aerosols Generated by a Customized eFlow Neos Nebulizer Delivered through Neonatal Nasal Prongs. Pharmaceutics, 2020, 12, 319.	4.5	14
127	Epidemiology, aetiology, prevention, diagnosis, management and complications of BPD. , 2021, , 515-520.		0
128	Bronchopulmonary dysplasia. , 2021, , 515-531.		0
129	Aerosol drug delivery to spontaneously-breathing preterm neonates: lessons learned. Respiratory Research, 2021, 22, 71.	3.6	29
130	Evidence for the Management of Bronchopulmonary Dysplasia in Very Preterm Infants. Children, 2021, 8, 298.	1.5	17

#	Article	IF	CITATIONS
131	Postnatal steroid management in preterm infants with evolving bronchopulmonary dysplasia. Journal of Perinatology, 2021, 41, 1783-1796.	2.0	31
132	Intraâ€ŧracheal surfactant/budesonide versus surfactant alone: Comparison of two consecutive cohorts of extremely preterm infants. Pediatric Pulmonology, 2021, 56, 2114-2124.	2.0	10
133	Budesonide mixed with surfactant did not affect neurodevelopmental outcomes at 6 or 18 months corrected age in observational cohorts. Journal of Perinatology, 2021, 41, 1681-1689.	2.0	5
134	Rates of Bronchopulmonary Dysplasia Following Implementation of a Novel Prevention Bundle. JAMA Network Open, 2021, 4, e2114140.	5.9	9
135	Assessment of Postnatal Corticosteroids for the Prevention of Bronchopulmonary Dysplasia in Preterm Neonates. JAMA Pediatrics, 2021, 175, e206826.	6.2	53
136	Efficacy of intratracheal budesonide-surfactant combined therapy in surfactant-insufficient rat lungs with lipopolysaccharide insult. Journal of the Chinese Medical Association, 2021, 84, 783-790.	1.4	0
137	Surfactant-Assisted Distal Pulmonary Distribution of Budesonide Revealed by Mass Spectrometry Imaging. Pharmaceutics, 2021, 13, 868.	4.5	0
138	Optimizing respiratory management in preterm infants: a review of adjuvant pharmacotherapies. Journal of Perinatology, 2021, 41, 2395-2407.	2.0	0
139	Bronkopulmoner Displazide İnhale Kortikosteroid Kullanımı. Turkish Journal of Pediatric Disease, 0, , 357-348.	0.0	0
140	Eligibility Criteria and Representativeness of Randomized Clinical Trials That Include Infants Born Extremely Premature: A Systematic Review. Journal of Pediatrics, 2021, 235, 63-74.e12.	1.8	7
141	Cognitive and academic outcomes of children born extremely preterm. Seminars in Perinatology, 2021, 45, 151480.	2.5	10
142	An Update on the Prevention and Management of Bronchopulmonary Dysplasia. Pediatric Health, Medicine and Therapeutics, 2021, Volume 12, 405-419.	1.6	11
143	Impact of early respiratory care for extremely preterm infants. Seminars in Perinatology, 2021, 45, 151478.	2.5	2
144	Medication Use in the Neonatal Intensive Care Unit and Changes from 2010Âto 2018. Journal of Pediatrics, 2022, 240, 66-71.e4.	1.8	50
145	Bronchopulmonary Dysplasia. , 2021, , 555-564.		0
146	How to decrease bronchopulmonary dysplasia in your neonatal intensive care unit today and "tomorrow― F1000Research, 2017, 6, 539.	1.6	20
147	Drug versus placebo randomized controlled trials in neonates: A review of ClinicalTrials.gov registry. PLoS ONE, 2017, 12, e0171760.	2.5	4
148	Bronchopulmonary dysplasia: how can we improve its outcomes?. Korean Journal of Pediatrics, 2019, 62, 367-373.	1.9	9

#	Article	IF	CITATIONS
149	Less is More: Modern Neonatology. Rambam Maimonides Medical Journal, 2018, 9, e0023.	1.0	8
150	Turkish Neonatal Society guideline on prevention and management of bronchopulmonary dysplasia. Turk Pediatri Arsivi, 2019, 53, 138-150.	0.9	6
151	Lipid enemas for meconium evacuation in preterm infants – a retrospective cohort study. BMC Pediatrics, 2021, 21, 454.	1.7	1
152	The Intertemporal Role of Respiratory Support in Improving Neonatal Outcomes: A Narrative Review. Children, 2021, 8, 883.	1.5	2
153	Oxygen Toxicity to the Immature Lung—Part II: The Unmet Clinical Need for Causal Therapy. International Journal of Molecular Sciences, 2021, 22, 10694.	4.1	7
154	The dilemma of persisting productive or wet cough in children without established chronic lung disease: How to treat and when to investigate. South African Respiratory Journal, 2016, 22, 26.	0.0	0
156	Statistical Analyses of Mutually Exclusive Competing Risks in Neonatal Studies. International Journal of Statistics in Medical Research, 2016, 5, 189-197.	1.0	0
157	Bronchopulmonary Dysplasia: a Modern View on Course and Outcomes. PediatriÄeskaâ Farmakologiâ, 2016, 13, 367-372.	0.4	2
159	Pulmonale Erkrankungen. , 2017, , 115-137.		0
160	FEATURES OF THE COMPLEX TREATMENT OF BRONCHOPULMONARY DYSPLASIA IN PRETERM INFANTS DEPENDING ON ITS SEVERITY. Neonatology Surgery and Perinatal Medicine, 2017, 7, 19-27.	0.1	0
161	Bronchopulmonary Dysplasia/Chronic Lung Disease of the Newborn. , 2018, , 887-911.		0
162	Lung Diseases: Problems of Steroid Treatment of Fetus and Newborn. , 2018, , 1015-1020.		0
163	Bronchopulmonary Dysplasia and Oxidative Stress in the Newborn. , 2019, , 309-323.		0
164	A practical, evidence-based approach to postneonatal management of children with bronchopulmonary dysplasia. Pediatric Respirology and Critical Care Medicine, 2019, 3, 42.	0.0	0
165	Criteria for the duration of anti-inflammatory therapy in children with bronchopulmonary dysplasia. Zaporožskij Medicinskij Žurnal, 2019, .	0.2	0
166	Presumed adrenal insufficiency in neonates treated with corticosteroids for the prevention of bronchopulmonary dysplasia. Journal of Perinatology, 2021, , .	2.0	2
167	Glucocorticoid Treatment for Bronchopulmonary Dysplasia. , 2020, , 259-273.		0
169	Prevention of bronchopulmonary dysplasia: current strategies. Chinese Journal of Contemporary Pediatrics, 2017, 19, 841-851.	0.2	2

#	Article	IF	CITATIONS
171	Effectiveness and safety of early combined utilization of budesonide and surfactant by airway for bronchopulmonary dysplasia prevention in premature infants with RDS: A metaâ€analysis. Pediatric Pulmonology, 2022, 57, 455-469.	2.0	5
172	Potential therapeutic role of budesonide to reduce COVID-19 severity. Journal of Infection and Public Health, 2022, 15, 109-111.	4.1	1
173	Corticosteroids in the prevention and treatment of infants with bronchopulmonary dysplasia: Part II. Inhaled corticosteroids alone or in combination with surfactants. Pediatric Pulmonology, 2022, 57, 787-795.	2.0	2
174	Corticosteroids in the prevention and treatment of infants with bronchopulmonary dysplasia: Part I. systemic corticosteroids. Pediatric Pulmonology, 2022, 57, 600-608.	2.0	3
175	Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?. Frontiers in Pediatrics, 2022, 10, 820259.	1.9	11
176	Hydrocortisone to Prevent Bronchopulmonary Dysplasia — Not a Silver Bullet. New England Journal of Medicine, 2022, 386, 1181-1183.	27.0	3
177	Respiratory support of infants born at 22–24 weeks of gestational age. Seminars in Fetal and Neonatal Medicine, 2022, 27, 101328.	2.3	12
178	Inhaled Pharmacotherapy for Neonates: A Narrative Review. , 2021, 57, 5-17.		1
179	Inhaled Budesonide in Neonatal Respiratory Distress Syndrome of Near-Term Neonates: A Randomized, Placebo-Controlled Trial. Journal of Pediatric Pharmacology and Therapeutics, 2022, 27, 38-44.	0.5	0
180	Moving bronchopulmonary dysplasia research from the bedside to the bench. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2022, 322, L804-L821.	2.9	7
181	The benefits, limitations and opportunities of preclinical models for neonatal drug development. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	4
184	Inhaled Corticosteroid Exposure in Hospitalized Infants with Bronchopulmonary Dysplasia. American Journal of Perinatology, 2022, 0, .	1.4	0
185	Predictors of extubation outcomes among extremely and very preterm infants: a retrospective cohort study. Jornal De Pediatria, 2022, 98, 648-654.	2.0	6
186	Postnatal Corticosteroids to Prevent or Treat Chronic Lung Disease Following Preterm Birth. Pediatrics, 2022, 149, .	2.1	17
187	Automated prediction of extubation success in extremely preterm infants: the APEX multicenter study. Pediatric Research, 2023, 93, 1041-1049.	2.3	10
188	Weaning and extubation from mechanical ventilation. , 2022, , 303-314.e5.		0
189	Pulmonary and neurodevelopmental outcomes following ventilation. , 2022, , 541-548.e3.		0
190	Pharmacologic therapies. , 2022, , 408-423.e7.		0

ARTICLE IF CITATIONS Evidence-based respiratory care., 2022, , 47-55.e1. 191 0 Thresholds for blood transfusion in extremely preterm infants: A review of the latest evidence from 1.9 two large clinical trials. Frontiers in Pediatrics, 0, 10, . Postnatal corticosteroid use for prevention or treatment of bronchopulmonary dysplasia in England 194 1.9 9 and Wales 2012–2019: a retrospective population cohort study. BMJ Open, 2022, 12, e063835. Complex roles of TGF-Î² signaling pathways in lung development and bronchopulmonary dysplasia. 2.9 American Journal of Physiology - Lung Cellular and Molecular Physiology, 2023, 324, L285-L296. Association Between Enteral Supplementation With High-Dose Docosahexaenoic Acid and Risk of 196 5.9 4 Bronchopulmonary Dysplasia in Preterm Infants. JAMA Network Open, 2023, 6, e233934. The prevention and management strategies for neonatal chronic lung disease. Expert Review of Respiratory Medicine, 2023, 17, 143-154. 2.5 Postnatal corticosteroid exposure in very preterm infants: A French cohort study. Frontiers in 198 3.5 3 Pharmacology, 0, 14, . Trends, Characteristic, and Outcomes of Preterm Infants Who Received Postnatal Corticosteroid: A 100 2.0 Cohort Study from 7 High-Income Countries. Neonatology, 2023, 120, 517-526. 200 Chronic Neonatal Respiratory Disorders., 2024, , 614-625.e4. 0 Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: study protocol for the international, multicenter, randomized 1.6 PĹUSS trial. Trials, 2023, 24, . Respiratory management and outcomes in high-risk preterm infants with development of a population 202 5.6 1 outcome dashboard. Thorax, 2023, 78, 1215-1222. Strengthening Reporting of Neonatal Trials. Pediatrics, 2023, 152, . 2.1 Outpatient management of established bronchopulmonary dysplasia: An update. Seminars in 204 2.5 0 Perinatology, 2023, , 151820. Management of bronchopulmonary dysplasia in Japan: A nationwide survey. Early Human Development, 1.8 2023, 186, 105867. Postnatal Corticosteroids To Prevent Bronchopulmonary Dysplasia. NeoReviews, 2023, 24, e691-e703. 206 0.8 0 Respiratory Distress Syndrome., 2024, , 66-77. Montelukast Sodium to Prevent and Treat Bronchopulmonary Dysplasia in Very Preterm Infants: A 208 2.4 0 Quasi-Randomized Controlled Trial. Journal of Clinical Medicine, 2023, 12, 7745. Budesonide and Surfactant Combination for Treatment of Respiratory Distress Syndrome in Preterm 209 Neonates and Evaluation Outcomes. Journal of Clinical Neonatology, 2023, 12, 135-141.

#	Article	IF	CITATIONS
210	Advanced Diagnostics of Respiratory Distress Syndrome in Premature Infants Treated with Surfactant and Budesonide through Computer-Assisted Chest X-ray Analysis. Diagnostics, 2024, 14, 214.	2.6	0
211	MORPHOLOGY OF BRONCHOPULMONARY DYSPLASIA IN PREMATURE INFANTS. , 2023, , 87-91.		0
212	Estimating the effect of diuretics and inhaled corticosteroids for evolving bronchopulmonary dysplasia in preterm infants. Paediatric and Perinatal Epidemiology, 0, , .	1.7	0
213	Prescribing practices of inhaled corticosteroids for premature infants in the neonatal intensive care unit. Journal of Perinatology, 0, , .	2.0	0
214	Outcomes of postnatal systemic corticosteroids administration in ventilated preterm newborns: a systematic review of randomized controlled trials. Frontiers in Pediatrics, 0, 12, .	1.9	0
215	Efficacy and safety of different inhaled corticosteroids for bronchopulmonary dysplasia prevention in preterm infants: a systematic review and meta-analysis. Respiratory Medicine and Research, 2024, , 101096.	0.6	0